case_images: PMC9942507_01
case_images: Immunohistochemical staining by D5F3 (Ventana, Oro Valley, Arizona) shows diffuse expression of ALK in the cytoplasm of tumor cells (original magnification x100).
case_images: OTT-16-109-g0001.jpg
case_images: PMC9942507_01_OTT-16-109-g0001.jpg
case_images: f0001
case_images: ALK in the tumor tissue from the previous surgery (Figure 1). At the same time, the previous surgical tumor tissue was detected by NGS based on a pan-cancer 8-gene panel. ALK-LIMS1 was detected.
case_images: The novel LIMS1-ALK fusion. Sequencing reads of LIMS1 and ALK are shown by the Integrative Genomics Viewer.
case_images: OTT-16-109-g0002.jpg
case_images: PMC9942507_01_OTT-16-109-g0002.jpg
case_images: f0002
case_images: The ALK-LIMS1 was fused by intron 20 of ALK to intron 1 of LIMS1 and retained the promotor region and the entire intracellular kinase domain, respectively (Figure 2A and B).
case_images: Images of liver computed tomography (CT) scans of the patient before (A) and after (B) crizotinib.
case_images: OTT-16-109-g0003.jpg
case_images: PMC9942507_01_OTT-16-109-g0003.jpg
case_images: f0003
case_images: Two months later, the right upper lung lesion and liver (Figure 3) progressed and the left pleural and pelvic effusions appeared.
case_images: The timeline from diagnosis of NSCLC to different stages of therapeutic regime and tumor evaluation and death.
case_images: OTT-16-109-g0004.jpg
case_images: PMC9942507_01_OTT-16-109-g0004.jpg
case_images: f0004
case_images: The treatment timeline and tumor evaluation are presented in Figure 4.